Followers | 2 |
Posts | 1472 |
Boards Moderated | 0 |
Alias Born | 07/20/2016 |
Sunday, October 21, 2018 12:50:56 PM
Director, Biomarkers
Job Locations US-NJ-Princeton
Posted Date 2 days ago(10/19/2018 2:31 PM)
ID
2018-1130
# of Openings
1
Category
Biotech/Pharmaceuticals
Overview
Advaxis Inc. is an immunotherapy company located in Princeton, NJ that develops products based on a proprietary live-attenuated vector technology to develop immunotherapies for cancer. Our programs encompass a late stage product in HPV+ associated cancers, ongoing programs in prostate cancer, and our future focus on neoantigen targeting immunotherapies. Our highly innovative and differentiated ADXS-NEO program provides individual neoantigen-targeted treatments based on identification of a patients’ own specific mutations identified from whole exome sequencing of tumor DNA. This program is already in the clinic and has been partnered with Amgen. Our ADXS-HOT programs employ multiple cancer type specific, “off-the-shelf” mutational hotspot-targeting immunotherapies. This first IND under our HOT program has been allowed for our non-small lung cancer (NSCLC) drug candidate and the first patient is expected to be dosed by the end of this year. We have several other drug candidates from the HOT program for prostate, bladder and other cancers at various stages behind the NSCLC drug candidate.
The challenge of immune monitoring and biomarker evaluation for neoantigen-based treatments is quite unique, and a critical pharmacodynamic index of treatment effects and this role will be at the center of the data generation and analysis efforts correlated with clinical treatment outcomes. We are seeking a highly motivated individual to join us as Director, Biomarkers. You will collaborate with the Research and Development and Clinical Development teams in this critical translational role in the exciting new area of cancer immunotherapy. Under minimal supervision, the successful Director candidate will be expected to develop immunologic monitoring and biomarker plans in collaboration with the research and development and clinical operations, assist in protocol development and site training, identify and vet third party laboratory service vendors, coordinate and oversee the collection, transport and analyses of clinical specimens for clinical trials organize and analyze results, coordinate the development of laboratory manuals, participate in the analysis and interpretation of immunologic and correlative findings, and communicate findings internally and at scientific meetings. You will also be asked to perform other duties as required. In this role you will report to the Chief Scientific Officer, with accountability to the Senior Director R&D, the Chief Medical Officer, and the clinical operations team.
Recent ADXS News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 12:13:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2024 09:30:45 PM
- Form DEFM14C - Definitive information statement relating to merger or acquisition • Edgar (US Regulatory) • 03/05/2024 01:16:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 09:30:46 PM
- Form PREM14C - Preliminary information statements relating to merger or acquisition • Edgar (US Regulatory) • 02/20/2024 10:22:48 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:26:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 07:16:21 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/12/2024 04:58:05 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/12/2024 01:27:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 10:15:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 01:51:21 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 01/03/2024 09:18:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 02:04:41 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 11/21/2023 02:00:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 02:00:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 09:04:59 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/08/2023 09:01:18 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/03/2023 03:46:10 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/03/2023 03:45:26 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/03/2023 03:43:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 11:08:02 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/31/2023 11:05:10 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 10/23/2023 10:45:21 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM